Predicting survival in head and neck squamous cell carcinoma from TP53 mutation

Human Genetics

Volumn 134, Issue 5, 2015, Pages 497-507

  Masica, David L ^a   Li, Shuli ^b   Douville, Christopher ^a   Manola, Judith ^b   Ferris, Robert L ^c   Burtness, Barbara ^d   Forastiere, Arlene A ^e   Koch, Wayne M ^e   Chung, Christine H ^e   Karchin, Rachel ^a,e  

^a Johns Hopkins University   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d FOX CHASE CANCER CENTER   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; TP53 PROTEIN, HUMAN;

ALGORITHM; BIOLOGY; COMPARATIVE STUDY; DISEASE COURSE; EVALUATION STUDY; GENETICS; HEAD AND NECK TUMOR; HUMAN; MEDICAL GENETICS; MUTATION; PATHOPHYSIOLOGY; PROCEDURES; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL ANALYSIS;

ALGORITHMS; CARCINOMA, SQUAMOUS CELL; COMPUTATIONAL BIOLOGY; DISEASE PROGRESSION; GENETICS, MEDICAL; HEAD AND NECK NEOPLASMS; HUMANS; MUTATION; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84939895480     PISSN: 03406717     EISSN: 14321203     Source Type: Journal    
DOI: 10.1007/s00439-014-1470-0     Document Type: Article

References (57)

1. Adzhubei IA et al (2010) A method and server for predicting damaging missense mutations. Nat Meth 7: 248–249, http://www.nature.com/nmeth/journal/v7/n4/suppinfo/nmeth0410-248_S1.html
2. Ahmed AA et al (2010) Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary. J Pathol 221:49–56. doi:10.1002/path.2696
3. Bartel F et al (2008) Both germ line and somatic genetics of the p53 pathway affect ovarian cancer incidence and survival. Clin Cancer Res 14:89–96. doi:10.1158/1078-0432.ccr-07-1192
4. Bisio A, Ciribilli Y, Fronza G, Inga A, Monti P (2014) TP53 mutants in the tower of babel of cancer progression. Hum Mutant n/a-n/a. doi:10.1002/humu.22514
5. Bonnet C et al (2008) Screening BRCA1 and BRCA2 unclassified variants for splicing mutations using reverse transcription PCR on patient RNA and an ex vivo assay based on a splicing reporter minigene. J Med Genet 45:438–446. doi:10.1136/jmg.2007.056895
6. Bradley PJ, MacLennan K, Brakenhoff RH, Leemans CR (2007) Status of primary tumour surgical margins in squamous head and neck cancer: prognostic implications. Current Opin Otolaryngol Head Neck Surg 15:74–81
7. Carter H et al (2009) Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res 69:6660–6667. doi:10.1158/0008-5472.can-09-1133
8. Carter H, Douville C, Stenson P, Cooper D, Karchin R (2013) Identifying mendelian disease genes with the variant effect scoring tool. BMC Genom 14:S3
9. Chan PA et al (2007) Interpreting missense variants: comparing computational methods in human disease genes CDKN2A, MLH1, MSH2, MECP2, and tyrosinase (TYR). Hum Mutat 28:683–693. doi:10.1002/humu.20492
10. Cox IDR (1970) Analysis of binary data. Methuen and Company Ltd, London, pp 61–62
11. Cox DR (1972) Regression models and life tables. JR stat soc B 34:187–220
12. Darcy KM et al (2008) Associations between p53 overexpression and multiple measures of clinical outcome in high-risk, early stage or suboptimally-resected, advanced stage epithelial ovarian cancers: a Gynecologic Oncology Group study. Gynecologic Oncology 111:487–495. doi:10.1016/j.ygyno.2008.08.020
13. de Graeff P et al. (2009) Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer 101, pp. 149–159, http://www.nature.com/bjc/journal/v101/n1/suppinfo/6605112s1.html
14. Desmet FOO et al (2009) Human splicing finder: an online bioinformatics tool to predict splicing signals. Nucleic Acids Res 37:e67. doi:10.1093/nar/gkp215
15. Dohner H et al (1995) p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood 85:1580–1589
16. Douville C et al (2013) CRAVAT: cancer-related analysis of variants toolkit. Bioinformatics 29:647–648. doi:10.1093/bioinformatics/btt017
17. El-Deiry WS et al (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817–825. doi:10.1016/0092-8674(93)90500-P
18. Ferris RL et al (2014) Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res. doi:10.1158/1078-0432.ccr-13-2617
19. Gentile M, Bergman Jungeström M, Olsen KE, Söderkvist P, Wingren S (1999) p53 and survival in early onset breast cancer: analysis of gene mutations, loss of heterozygosity and protein accumulation. Eur J Cancer 35:1202–1207. doi:10.1016/S0959-8049(99)00121-5
20. Gonzalez D et al (2011) Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial. J Clin Oncol 29:2223–2229. doi:10.1200/jco.2010.32.0838
21. Greaves M, Maley CC (2012) Clonal evolution in cancer. Nature 481: 306–313, http://www.nature.com/nature/journal/v481/n7381/abs/nature10762.html—supplementary-information
22. Hicks S, Wheeler DA, Plon SE, Kimmel M (2011) Prediction of missense mutation functionality depends on both the algorithm and sequence alignment employed. Hum Mutat 32:661–668. doi:10.1002/humu.21490
23. HØGdall EVS et al (2008) Distribution of p53 expression in tissue from 774 Danish ovarian tumour patients and its prognostic significance in ovarian carcinomas. APMIS 116:400–409. doi:10.1111/j.1600-0463.2008.00917.x
24. Integrated genomic analyses of ovarian carcinoma. (2011) Nature 474: pp. 609–615, http://www.nature.com/nature/journal/v474/n7353/abs/nature10166-f1.2.html—supplementary-information
25. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481
26. Kato S et al (2003) Understanding the function, Äìstructure and function, Äìmutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci 100:8424–8429. doi:10.1073/pnas.1431692100
27. Keats JJ et al (2012) Clonal competition with alternating dominance in multiple myeloma. Blood 120:1067–1076. doi:10.1182/blood-2012-01-405985
28. Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 4:1073–1081
29. Lothe RA et al (1995) Deletion of 1p loci and microsatellite instability in colorectal polyps. Genes Chromosom Cancer 14:182–188
30. Ludwig JA, Weinstein JN (2005) Biomarkers in Cancer Staging, Prognosis and Treatment Selection. Nat Rev Cancer 5:845–856
31. Marcel V et al (2011) Biological functions of p53 isoforms through evolution: lessons from animal and cellular models. Cell Death Differ 18:1815–1824
32. Marusyk A, Almendro V, Polyak K (2012) Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 12:323–334
33. Masica DL, Sosnay PR, Cutting GR, Karchin R (2012) Phenotype-optimized sequence ensembles substantially improve prediction of disease-causing mutation in cystic fibrosis. Hum Mutat 33:1267–1274. doi:10.1002/humu.22110
34. Mehta CR, Patel NR, Tsiatis AA (1984) Exact significance testing to establish treatment equivalence with ordered categorical data. Biometrics, 819–825
35. Muller PAJ, Vousden KH (2013) p53 mutations in cancer. Nat Cell Biol 15:2–8
36. Newcomb EW et al (1998) Survival of patients with glioblastoma multiforme is not influenced by altered expression of P16, P53, EGFR, MDM2 or Bcl-2 genes. Brain Pathol 8:655–667. doi:10.1111/j.1750-3639.1998.tb00191.x
37. Olivier M (2013) In p53 in the Clinics. In: Hainaut P, Olivier M, Wiman KG (eds). Springer, New York, Ch. 8, pp. 127–146
38. Parsons DW et al (2011) The genetic landscape of the childhood cancer medulloblastoma. Science 331:435–439. doi:10.1126/science.1198056
39. Petitjean A et al (2007) Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 28:622–629. doi:10.1002/humu.20495
40. Peto R, Peto J (1972) Asymptotically efficient rank invariant test procedures. JR Stat Soc 135:185–206
41. Poeta ML et al (2007) TP53 Mutations and Survival in Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med 357:2552–2561. doi:10.1056/NEJMoa073770
42. Powell B, Soong R, Iacopetta B, Seshadri R, Smith DR (2000) Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. Clin Cancer Res 6:443–451
43. Robles AI, Harris CC (2010) Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol 2:a001016. doi:10.1101/cshperspect.a001016
44. Rossi D et al (2009) The Prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 15:995–1004. doi:10.1158/1078-0432.ccr-08-1630
45. Shihab HA et al (2013) Predicting the functional, molecular, and phenotypic consequences of amino acid substitutions using hidden markov models. Hum Mutat 34:57–65. doi:10.1002/humu.22225
46. Simmons ML et al (2001) Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 61:1122–1128
47. Soussi T, Kato S, Levy PP, Ishioka C (2005) Reassessment of the TP53 mutation database in human disease by data mining with a library of TP53 missense mutations. Hum Mutat 25:6–17. doi:10.1002/humu.20114
48. Steels E et al (2001) Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 18:705–719
49. Tabor MP et al (2001) Persistence of genetically altered fields in head and neck cancer patients: biological and clinical implications. Clin Cancer Res 7:1523–1532
50. Tavtigian SV, Greenblatt MS, Lesueur F, Byrnes GB (2008) In silico analysis of missense substitutions using sequence-alignment based methods. Hum Mutat 29:1327–1336. doi:10.1002/humu.20892
51. Thusberg J, Olatubosun A, Vihinen M (2011) Performance of mutation pathogenicity prediction methods on missense variants. Hum Mutat 32:358–368. doi:10.1002/humu.21445
52. Uno H, Cai T, Pencina MJ, D’Agostino RB, Wei LJ (2011) On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data. Stat Med 30:1105–1117. doi:10.1002/sim.4154
53. Vogelstein B et al (2013) Cancer Genome Landscapes. Science 339:1546–1558. doi:10.1126/science.1235122
54. Weller M et al (2009) Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma network. J Clin Oncol 27:5743–5750. doi:10.1200/jco.2009.23.0805
55. Wong KK et al (2013) Poor survival with wild-type TP53 ovarian cancer? Gynecol Oncol 130:565–569. doi:10.1016/j.ygyno.2013.06.016
56. Yeo G, Burge CB (2004) Maximum entropy modeling of short sequence motifs with applications to RNA splicing signals. J Comput Biol 11:377–394
57. Zenz T et al (2010) TP53 Mutation and Survival in Chronic Lymphocytic Leukemia. J Clin Oncol 28:4473–4479. doi:10.1200/jco.2009.27.8762